Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.46 |
| ▸ | PPARG | P37231 | 8/20 | 0.46 |
| ▸ | PPARD | Q03181 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818856 | 1.00 | PPARA (0.46) | PPARAPPARGPPARDALDH1A1HPGD | |
| SCHEMBL2821856 | 1.00 | PPARA (0.46) | PPARAPPARGPPARDALDH1A1HPGD | |
| SCHEMBL2819716 | 0.90 | PPARA (0.49) | PPARAPPARGPPARD | |
| SCHEMBL2819721 | 0.90 | PPARA (0.49) | PPARAPPARGPPARD | |
| SCHEMBL2821653 | 0.90 | PPARA (0.49) | PPARAPPARGPPARD | |
| SCHEMBL2821457 | 0.86 | ALDH1A1 (0.37) | PPARAPPARGPPARDALDH1A1HPGD | |
| SCHEMBL2821458 | 0.86 | ALDH1A1 (0.37) | PPARAPPARGPPARDALDH1A1HPGD | |
| SCHEMBL2821960 | 0.86 | ALDH1A1 (0.37) | PPARAPPARGPPARDALDH1A1HPGD | |
| SCHEMBL2821602 | 0.81 | PPARA (0.49) | PPARAPPARGPPARD | |
| SCHEMBL2821913 | 0.75 | ALDH1A1 (0.37) | PPARAPPARGPPARDALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | claimed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | PPARA 1/4885PPARG 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.